Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide - Wikidata - wikimedia - TriplyDB

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

http://www.wikidata.org/entity/Q24647228

about

New viruses for cancer therapy: meeting clinical needs Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination Oncolytic virotherapy for human malignant mesothelioma: recent advances Oncolytic viruses as anticancer vaccines The use of the NIS reporter gene for optimizing oncolytic virotherapy MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma.Dynamics of multiple myeloma tumor therapy with a recombinant measles virus.Viral oncolysis - can insights from measles be transferred to canine distemper virus?Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.Remission of disseminated cancer after systemic oncolytic virotherapy Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors.Oncolytic virotherapy for ovarian cancer.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells Oncolytic virotherapy for hematological malignancies.Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus.Attenuated oncolytic measles virus strains as cancer therapeutics Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy.Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques.Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.Enhancing cytokine-induced killer cell therapy of multiple myeloma.HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth.Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61 Oncolytic measles virus strains as novel anticancer agents.Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.Engineered measles virus as a novel oncolytic therapy against prostate cancer.Measles virus for cancer therapy.Pharmacologic and chemical adjuvants in tumor virotherapy.The Na+/I- symporter (NIS): mechanism and medical impact.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models

P2860

Q24567699-87162DA4-4336-472F-9C80-986FB282DC1A Q24605512-A32806F8-ADDC-40F5-BDFE-C9594496271E Q26700080-DEB9EF8A-B5CD-43BF-A800-CD2EAE619B45 Q26826590-F5902B65-4064-46B7-AA47-6C066BD33CBB Q27025600-66B79F07-3D65-4DCA-AC56-59F5FD3482FD Q28083534-CE41E2F1-DB66-4616-AC4F-49DE49A2F955 Q30502129-3EEA8161-5003-4E90-936C-566AE60896AB Q33418048-D4CCD87D-CDE5-4136-9BAD-17FF74FF11D6 Q33441321-F7540D8F-4B86-48F8-98F8-9439BE577F11 Q33585559-8B336145-CF2E-411A-B885-2DE5F966B775 Q33652517-06721CE5-1EB6-4AAD-A8AD-89E1013266B6 Q33820717-63C2EFCB-8411-4C15-BECA-36B7BFB16139 Q34292273-5474E691-45C0-4DF4-AC60-E65AA8769789 Q34420326-162FDB73-48E7-4864-8D38-64F5F1D0909D Q34470472-282E6E5F-8451-4284-A777-20C28A21B253 Q35285887-4112FE61-40A3-4EB0-8A4D-5C6D931D57C1 Q35370655-4E1A488D-61E4-4BE1-BB8C-3ABD2E704736 Q35415103-9C56B236-326D-4FD5-8AC7-E322A368347E Q35597082-07AE89AC-5275-4115-90ED-81C30561A86F Q35687743-BD03FF9B-A3FD-4F0A-8659-22CDB028E40F Q35692095-89C371CF-2CD6-4108-A1E3-2466C8C8EF5B Q35785494-A09C65AC-C7A7-4E76-AA59-1ABB768319F0 Q35818876-F8E4FBC1-3055-4BCF-AC0B-DF03AB43D2D5 Q35823934-0FB99401-E827-4816-8E85-B74F81F6FD45 Q35876172-96A9BAD6-CBAE-464C-9D2F-93762987417B Q36014057-0FEB6F57-8D11-4F23-82F2-643502A5F08C Q36390054-EEED14F8-EFF6-49DB-972E-6717F6A9F8C2 Q36597119-7428C0F9-8F24-4D27-A1F2-4D6007D085F9 Q36892290-4BD2BB16-6352-4DF6-9D5C-C6CF786B473F Q37104963-0D35AE58-5E6B-4EB5-BB1D-CD2FC948286A Q37115384-89D0A1E9-DC1D-4A32-823C-90450EF1BE8E Q37138130-81F9E16A-87A9-4EDC-BFCC-049472612036 Q37261017-F2A5D9BF-8CCF-4B33-B4B1-1038DA997355 Q37280354-34F3945E-B316-430B-87C6-188E6811613E Q37332702-17AF63FF-3F1A-423F-900A-A62FDFC70F5C Q37388577-6A5F778A-738F-4255-923E-32074EBEDDA0 Q37492540-6E5D994F-053C-4ED0-A652-747CBEDDD600 Q37494004-19CC7C10-FC86-4853-B6DE-01DE6EDD1D65 Q37564490-A450B2D7-B289-4234-8D37-DDFB15C5FC19 Q37629550-E3381CC0-BF03-41F9-AC08-4A0FDB285C5C

P2860

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

http://www.wikidata.org/entity/Q24647228

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Preclinical pharmacology and t ...... th or without cyclophosphamide

@ast

Preclinical pharmacology and t ...... th or without cyclophosphamide

@en

Preclinical pharmacology and t ...... th or without cyclophosphamide

@nl

type

label

Preclinical pharmacology and t ...... th or without cyclophosphamide

@ast

Preclinical pharmacology and t ...... th or without cyclophosphamide

@en

Preclinical pharmacology and t ...... th or without cyclophosphamide

@nl

prefLabel

Preclinical pharmacology and t ...... th or without cyclophosphamide

@ast

Preclinical pharmacology and t ...... th or without cyclophosphamide

@en

Preclinical pharmacology and t ...... th or without cyclophosphamide

@nl

P1433

Q24647228-C9A9A8E8-5292-45BE-BC4A-2A670CA5F96B

P1476

Q24647228-6785597F-5510-4968-8565-2449F718B071

P2093

Q24647228-0765388F-AB3A-4522-8931-3BF1446BFBB9

Q24647228-0AE208FC-AAD9-4CB3-81CA-BBC076504F00

Q24647228-199260DE-9004-471D-9FF5-14A1801CD846

Q24647228-2E863AC3-D08B-4E5C-9215-BF3A9899022C

Q24647228-4B432762-391E-49E0-B7AF-247C1EB03D4F

Q24647228-55EE457B-F223-4139-98AD-2F7386FD820F

Q24647228-946639CC-EB06-484A-991F-0388A6677B4A

Q24647228-9A6D9FB6-7E4F-4211-ADF7-7DB9F1F0A24F

Q24647228-9F65FACB-C988-44AF-BD96-14B272B6CBA7

Q24647228-ABCDB45E-1668-4AA5-8B72-24291E8D37CE

P2860

Q24647228-0DEC5A04-B422-4B46-ACFB-173AAF92E149

Q24647228-1020ACE1-0C39-4E3D-B05A-BA10E2798C32

Q24647228-128E7882-5954-4A1C-8AF2-8292CC49BE0C

Q24647228-235E634E-5E68-42C1-B4BE-7B58C6F5B129

Q24647228-23E56BD1-4B9E-48F7-8792-3DA67E92ECF4

Q24647228-36DADA3C-DF59-4F25-AC54-5024F415785E

Q24647228-39E0CEAA-9AD0-47F8-B210-4AB0DC7A3C8C

Q24647228-3AE137BF-A7AF-4469-839F-646C2D05FB17

Q24647228-49C4B877-AE93-44BF-B32C-D1127D58FF44

Q24647228-49FEED31-B621-4ECA-AC47-8C7CA68EA336

P2888

Q24647228-D5FB6566-63EE-4826-ABCA-6749ED257EF2

P304

Q24647228-B7879D45-346F-46BE-BAF9-059106448153

P31

Q24647228-E765E56D-CA75-486C-93E1-26A313155B4A

P356

Q24647228-51DC3D8B-AA65-4BF1-9A00-37B96753CB3E

P407

Q24647228-24D6DBE5-29EF-4E70-9732-A8CC6DA51C86

P433

Q24647228-D2223546-7872-439D-A0F3-9651942DA002

P478

Q24647228-7B99D106-5B12-4C3E-9E29-E22F94F872DC

P577

Q24647228-ABA0E0EE-8234-4A6A-AE58-719234205D67

P5875

Q24647228-F2C367AA-DF3C-4D7B-B584-9DACFE64BECB

P6179

Q24647228-2A43F43B-982F-4220-9AAE-738094B0601A

P698

Q24647228-C4143203-6FC4-4BDD-AD8A-52998C17BEC2

P921

Q24647228-3BF5822F-F568-4371-B455-E84333947518

Q24647228-6783CE24-7156-44CC-9FAC-6656000D0AD9

Q24647228-9AF23597-E2AE-4DF1-A891-F91013E820B1

Q24647228-EDAC72D8-24E6-4AB2-93E8-8F4C33FC986B

P932

Q24647228-93B8D7E8-9A0B-4A5F-997B-EB818850AF6D

P356

SJ.CLPT.6100409

P1433

Clinical Pharmacology & Therapeutics

P1476

Preclinical pharmacology and t ...... th or without cyclophosphamide

@en

P2093

A Dispenzieri

http://www.w3.org/2001/XMLSchema#string

A Welch

http://www.w3.org/2001/XMLSchema#string

D Dingli

http://www.w3.org/2001/XMLSchema#string

G Griesmann

http://www.w3.org/2001/XMLSchema#string

J M Reid

http://www.w3.org/2001/XMLSchema#string

K Schweikart

http://www.w3.org/2001/XMLSchema#string

K-W Peng

http://www.w3.org/2001/XMLSchema#string

M E Harvey

http://www.w3.org/2001/XMLSchema#string

M Federspiel

http://www.w3.org/2001/XMLSchema#string

M J Kuffel

http://www.w3.org/2001/XMLSchema#string

P2860

The human CD46 molecule is a receptor for measles virus (Edmonston strain)

SLAM (CDw150) is a cellular receptor for measles virus

Membrane cofactor protein (MCP; CD46) expression in transgenic mice

Measles virus spread and pathogenesis in genetically modified mice.

Model Systems: transgenic mouse models for measles pathogenesis.

Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

Propagation in tissue cultures of cytopathogenic agents from patients with measles.

Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses

Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

P2888

sj.clpt.6100409

P304

700-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.CLPT.6100409

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5874155

http://www.w3.org/2001/XMLSchema#string

P6179

1021286227

http://www.w3.org/2001/XMLSchema#string

P698

17971816

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

2769566

http://www.w3.org/2001/XMLSchema#string